We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceuticals and Natco Pharma have announced the launch of the first generic versions of Revlimid (lenalidomide) in the U.S., a move that will take a bite out of Bristol Myers Squibb’s (BMS) profit from the blockbuster blood cancer drug. Read More
A newly proposed bill would make it easier for the FDA to expeditiously remove drugs marketed on accelerated approvals if they don’t live up to their clinical promise. Read More
In the late-stage study, Jardiance was shown to reduce relative risk of heart failure-related death or hospitalization by 21 percent vs. placebo. Read More
Gilead Sciences is touting a phase 3 win for its drug-antibody conjugate Trodelvy (sacituzumab govitecan-hziy), saying it significantly improved progression-free survival in women with metastatic, treatment-resistant breast cancer. Read More
The FDA has approved GlaxoSmithKline’s blockbuster cancer drug Opdivo (nivolumab) in combination with chemotherapy for adult patients with resectable nonsmall-cell lung cancer (NSCLC). It is the first approved neoadjuvant treatment for patients with early-stage NSCLC. Read More
Various supply-chain resilience measures are needed to ensure U.S. drug production before the next pandemic or other natural disaster, a National Academy of Sciences, Engineering and Medicine (NASEM) expert panel advised in a new report. Read More
Nearly $80 million will be invested to bolster commercial-scale manufacturing for companies producing innovate technologies, such as cell and gene therapies. Read More